Virogin Company
They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlytic™ technical platform for improved cancer treatment. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.
Investor Type:
Undisclosed
Technology:
Drug Design
Investment Stage:
Venture
Founded Date:
2015
Industry:
Drug Discovery
Employee Number:
Undisclosed
Funding Status:
N/A
Number Of Exists:
1
Headquarters:
Shenzhen, Guangdong, China